Abstract
Selumetinib plus dacarbazine prolongs progression-free survival in BRAF-mutant melanoma.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Benzimidazoles / administration & dosage*
-
Dacarbazine / administration & dosage*
-
Disease-Free Survival
-
Humans
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / mortality
-
Mutation
-
Proto-Oncogene Proteins B-raf / genetics
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / mortality
Substances
-
AZD 6244
-
Benzimidazoles
-
Dacarbazine
-
Proto-Oncogene Proteins B-raf